Silva-Gomez et al. [45] revealed that pirfenidone, a ligand/agonist of PPARγ, can prevent HCC development via modifying NF-κB p65/p50 signaling and translocation, preventing inflammation, and increasing p53 activity as well as caspase 3 activation. Here, NFKB1 is linked to hepatocellular carcinoma.